Texas had offered up an incentives package that — including free land, tax abatements and training — would have been worth more than $300 million. Amid the coronavirus pandemic, the slew of state, ...
Fujifilm Diosynth, a Japanese contract drug manufacturer with a large presence in Research Triangle Park, will invest $2 billion into a new facility in the U.S. — and North Carolina could be the ...
A rendering of the $2 billion cell culture manufacturing facility for which Fujifilm Diosynth Biotechnologies broke ground last week in Holly Springs, NC. [Fujifilm Diosynth Biotechnologies] The cell ...
THOUSAND OAKS, CALIF., Nov. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced ...
FUJIFILM Diosynth Biotechnologies (FDB) will provide essential drug substance and drug product manufacturing, under accelerated timelines, for NeuExcell’s first-in-human clinical studies Drug ...
RESEARCH TRIANGLE PARK – Life science giant Fujifilm Diosynth Biotechnologies is adding more jobs and manufacturing capacity in the Triangle. Some 145 new jobs – including researchers and scientists – ...
PHILADELPHIA & COLLEGE STATION, Texas--(BUSINESS WIRE)--Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery ...
Building on the company's investment of $2 billion in 2021, the Wake County, NC plant is set to be the largest end-to-end biopharma manufacturing facility in North America. In Holly Springs, North ...
Under the terms of the agreement, FUJIFILM Diosynth Biotechnologies will provide US-based manufacturing for Regeneron over the 10-year period through current and planned expansions at its new ...
Fujifilm Diosynth Biotechnologies plans to add 680 high-paying jobs at its Holly Springs campus, executives said Thursday — part of a $1.2 billion expansion of what is expected to be one of the ...
A rendering of Fujifilm Diosynth Biotechnologies’ planned $2 billion cell culture manufacturing facility. The company is eligible for up to $21.7 million in state grants tied to capital investment and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results